Testing Dazodalibep for Moderate-to-Severe Sjögren’s Syndrome

This Phase 3 study is evaluating whether an investigational drug called dazodalibep is safe and effective for adults with Sjögren's syndrome who have moderate-to-severe systemic (whole-body) disease activity.

Duration

~ 6 months

Visits

6 – 8 clinic visits

Compensation

Yes, Provided

Location

Bellevue, WA

About This Trial

This Phase 3 study is evaluating whether an investigational drug called dazodalibep is safe and effective for adults with Sjögren’s syndrome who have moderate-to-severe systemic (whole-body) disease activity.

Participants are randomly assigned to receive either dazodalibep or a placebo.

Sjögren’s syndrome is an autoimmune disease that causes dry eyes, dry mouth, and can affect other organs. The study is blinded, meaning neither participants nor the study team know which treatment is being received.

Condition: Sjögren’s Syndrome

Learn more: View on ClinicalTrials.gov

Check Your Eligibility Screening

Answer a few questions to see if you may qualify for our gout clinical trial.

Eligibility screening is not available at the moment.

This is completely confidential, your answers are processed locally and are not stored or transmitted. Only your contact information is saved if you choose to submit it.

Other Trials

We have several clinical trials and you may be eligible for more than one. Lets find out.

Testing Dazodalibep for Moderate-to-Severe Sjögren’s Syndrome

This Phase 3 study is evaluating whether an investigational drug called dazodalibep is safe and effective for adults with Sjögren's syndrome who have moderate-to-severe systemic (whole-body) disease activity.

About This Trial

Check Your Eligibility Screening

Other Trials

Evaluating Sarilumab for Adults with Early Polymyalgia Rheumatica (PMR)

Testing Natrunix Combined with Methotrexate for Rheumatoid Arthritis

Using a Molecular Test to Guide Treatment Choice for Rheumatoid Arthritis

Continued Secukinumab Treatment for Prior Novartis Study Participants

V Secukinumab Safety Study for Giant Cell Arteritis or Polymyalgia Rheumatica

Testing a New Combination Treatment for Gout

Testing a New Treatment (LY3871801) for Moderate-to-Severe Rheumatoid Arthritis

Blood Sample Study for Rheumatoid Arthritis Patients Starting a New Medication

AR882 for Gout Patients Who Have Not Responded to Prior Uricase Therapy

Testing LY2439821 for Moderate-to-Severe Plaque Psoriasis

Testing Nipocalimab for Moderate-to-Severe Sjögren’s Disease

Testing Afimetoran for Active Lupus (SLE)